MX356958B - Análogos de péptido-2 tipo glucagón (glp-2). - Google Patents

Análogos de péptido-2 tipo glucagón (glp-2).

Info

Publication number
MX356958B
MX356958B MX2014013319A MX2014013319A MX356958B MX 356958 B MX356958 B MX 356958B MX 2014013319 A MX2014013319 A MX 2014013319A MX 2014013319 A MX2014013319 A MX 2014013319A MX 356958 B MX356958 B MX 356958B
Authority
MX
Mexico
Prior art keywords
glp
analogues
glucagon
peptide
gly2
Prior art date
Application number
MX2014013319A
Other languages
English (en)
Other versions
MX2014013319A (es
Inventor
Ditte Riber
Rasmus Just
Kirsten Lindegaard Bovbjerg
Wayne Shaun Russell
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of MX2014013319A publication Critical patent/MX2014013319A/es
Publication of MX356958B publication Critical patent/MX356958B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención se refiere a un análogo de GLP-2 representado por la fórmula general II: R1-His-X2-X3-Gly-X5-Phe-X7 -Ser-Glu.Leu-Ala-X12-X13-X14-X15-X16-X17-Ala-X19.X20-X21-Phe-lle- X24-Trp-Leu-X27-X28-X29-X30-X31-X32-X33-X34-R2 (II) o una sal o solvato farmacéuticamente aceptable del mismo, caracterizado porque R1 es hidrógeno, alquilo C1-4 (por ejemplo, metilo) acetilo, fomilo, benzoílo o trifluroacetilo; X2. Gly, ala o Aib; X3 es Glu, Gln o Asp; X5 es Ser o Thr; X7 es Ser o Thr; X12 es Thr, Ser o Lys; X13 es lle, Leu, Val, Tyr, Phe o Gln; X14 es Leu o Met; X15 es Asp o Glu; X16 es Gly, Ser, Ala, Glu o Lys; X17 es Gln o Lys; X19 es Ala o Val: X20 es Arg, Lys o His; X21 es Asp, Glu o Leu; X24 es Asn, Ala, Glu o Lys; X27 es lle, Leu, Val, Glu o Lys; X28 es Gln, Asn, Lys, Ser, Y1o ausente; X29 es Thr, Ala, Y1 o ausente; X30 es Lys, Y1 o ausente; X30 es Lys, Y1 o ausente; X31 es lle, Pro, Y1 o ausente; X32 es Thr, Y1 o ausente; X33 es Asp, Asn, Y1 o ausente; X34 es Y1 o ausente; Y1 es Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, o Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser; y R2 es NH2 u OH; en el que el análogo de GLP-2 contiene no más de un Y1; si cualquiera de X28 a X33 es Y1, aquellas posiciones X29 a X34 cadena debajo de esta Y1 están ausentes; si cualquiera de X28 a X33 está ausente, aquellas posiciones X29 a X33 cadena debajo de esa posición también están ausentes; y donde el análogo de GLP-2 tiene actividad en los receptores GLP-1 y GLP-2, y actividad mayor en el receptor GLP-1 que el GLP-2 humano de tipo silvestre.
MX2014013319A 2012-05-03 2013-05-03 Análogos de péptido-2 tipo glucagón (glp-2). MX356958B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261642447P 2012-05-03 2012-05-03
US201361785852P 2013-03-14 2013-03-14
PCT/EP2013/059320 WO2013164484A1 (en) 2012-05-03 2013-05-03 Glucagon-like-peptide-2 (glp-2) analogues

Publications (2)

Publication Number Publication Date
MX2014013319A MX2014013319A (es) 2015-07-06
MX356958B true MX356958B (es) 2018-06-20

Family

ID=48428462

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013319A MX356958B (es) 2012-05-03 2013-05-03 Análogos de péptido-2 tipo glucagón (glp-2).

Country Status (14)

Country Link
US (3) US9453064B2 (es)
EP (1) EP2844670B1 (es)
JP (1) JP6298044B2 (es)
KR (1) KR20150006052A (es)
CN (1) CN104540850B (es)
AU (1) AU2013255752B2 (es)
BR (1) BR112014027345A2 (es)
CA (1) CA2872315A1 (es)
EA (1) EA028929B1 (es)
HK (1) HK1208238A1 (es)
IN (1) IN2014DN09782A (es)
MX (1) MX356958B (es)
TR (1) TR201802689T4 (es)
WO (1) WO2013164484A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007319066B2 (en) 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
US9453064B2 (en) 2012-05-03 2016-09-27 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
US10442847B2 (en) 2012-07-23 2019-10-15 Zealand Pharma A/S Glucagon analogues
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2934569A1 (en) 2012-12-21 2015-10-28 Sanofi Exendin-4 derivatives
BR112016008115B1 (pt) 2013-10-17 2024-03-12 Boehringer Ingelheim International Gmbh Análogos de glucagon acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
BR112016009995B1 (pt) 2013-11-06 2023-04-18 Zealand Pharma A/S Compostos agonistas triplos glucagon-glp-1-gip
BR112016009889B1 (pt) 2013-11-06 2023-11-28 Zealand Pharma A/S Análogo do gip, composição farmacêutica compreendendo um análogo do gip, ou um sal farmaceuticamente aceitável do mesmo, e seu uso
TW201609799A (zh) * 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609800A (zh) * 2013-12-13 2016-03-16 賽諾菲公司 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
BR112017008659A2 (pt) 2014-10-29 2018-01-30 Zealand Pharma As ?métodos e compostos de agonista de gip?
KR20170078668A (ko) * 2014-10-31 2017-07-07 구브라 에이피에스 이중 glp-1r 및 glp-2r 작용제 활성을 갖는 조성물 및 펩티드
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
LT3393496T (lt) 2015-12-23 2023-12-11 The Johns Hopkins University Ilgo veikimo glp-1r agonistas, kaip neurologinių ir neurodegeneracinių būklių terapija
JP6700150B2 (ja) * 2016-10-03 2020-05-27 東京エレクトロン株式会社 パーティクル捕集装置、パーティクル捕集方法、およびパーティクル捕集システム
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
RU2756011C2 (ru) * 2016-12-09 2021-09-24 Зилэнд Фарма А/С Glp-1/glp-2 двойные агонисты
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
WO2018104559A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Glp-1/glp-2 dual agonists
DK3638291T3 (da) * 2017-06-16 2021-10-18 Zealand Pharma As Dosisregimer til indgivelse af glucagon-lignende-peptid-2 (GLP-2)-analoger
GB201710822D0 (en) * 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia
KR20200085763A (ko) 2017-11-06 2020-07-15 샤이어-엔피에스 파마슈티칼즈, 인크. 수술전, 수술동안 또는 수술후 투여용 glp-2 유사체 및 펩티바디
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
US20200254065A1 (en) 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
US20230212227A1 (en) 2019-06-14 2023-07-06 Zealand Pharma A/S Pharmaceutical parenteral composition of dual glp1/2 agonist
CA3156985A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
CN111329995B (zh) * 2020-02-18 2022-11-11 河南中医药大学 Glp-2类似物在制备防治pd药物中的应用及防治pd的药物
IL298306A (en) 2020-05-19 2023-01-01 Kallyope Inc ampk operators
CA3182260A1 (en) 2020-06-09 2021-12-16 Gleb Feldman Manufacture, formulation and dosing of apraglutide
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5912229A (en) 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
DE69717092T2 (de) 1996-03-01 2003-07-24 Novo Nordisk As Gebrauch einer pharmazeutischen Zusammensetzung, enthaltend ein appetitzügelndes Peptid
ES2188929T3 (es) 1996-04-12 2003-07-01 Ontario Inc 1149336 Analogos 2-peptidicos de tipo glucagon.
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US20020025933A1 (en) 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
CA2265900C (en) 1996-09-09 2007-07-31 Zealand Pharmaceuticals A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
US6051557A (en) 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
DE69819488T2 (de) 1997-05-16 2004-08-26 1149336 Ontario Inc., Toronto Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
DE04029691T1 (de) 1998-02-02 2007-11-08 Trustees Of Tufts College, Medford Verwendung von Dipetidylpeptidasehemmer zur Regulierung des Glukosemetabolismus
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU7421598A (en) 1998-05-11 1999-11-29 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
ES2315226T3 (es) 1999-03-17 2009-04-01 Novo Nordisk A/S Metodo de acilacion de peptidos y proteinas.
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US20030040478A1 (en) 1999-12-08 2003-02-27 Drucker Daniel J Chemotherapy treatment
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
DE60134251D1 (de) 2000-09-18 2008-07-10 Sanos Bioscience As Verwendung von glp-2-peptiden
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
EP1980572A1 (en) 2001-02-16 2008-10-15 ConjuChem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
JP2005506956A (ja) 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
PL376223A1 (en) * 2002-10-14 2005-12-27 Novo Nordisk As Glucagon - like peptide - 2 variants
CN1705681A (zh) * 2002-10-14 2005-12-07 诺沃挪第克公司 Glp－2化合物、制剂及其用途
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005082404A2 (en) * 2004-02-27 2005-09-09 Novo Nordisk A/S Glp-2 derivatives modified by lipophilic substituents
US7847061B2 (en) 2004-11-01 2010-12-07 Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
MX2007013431A (es) 2005-05-04 2008-01-18 Zealand Pharma As Analogos del peptido 2 semejante al glucagon.
AU2007319066B2 (en) 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
AU2008365555B2 (en) * 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
UY33462A (es) * 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
MX344219B (es) 2011-05-18 2016-12-07 Mederis Diabetes Llc Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
US9453064B2 (en) 2012-05-03 2016-09-27 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues

Also Published As

Publication number Publication date
CN104540850A (zh) 2015-04-22
US9453064B2 (en) 2016-09-27
EP2844670A1 (en) 2015-03-11
BR112014027345A2 (pt) 2019-09-03
US20150125431A1 (en) 2015-05-07
EA201491934A1 (ru) 2015-07-30
CA2872315A1 (en) 2013-11-07
HK1208238A1 (en) 2016-02-26
IN2014DN09782A (es) 2015-07-31
AU2013255752A1 (en) 2014-12-18
TR201802689T4 (tr) 2018-03-21
US20160355563A1 (en) 2016-12-08
EP2844670B1 (en) 2017-12-06
US9969787B2 (en) 2018-05-15
US20180298077A1 (en) 2018-10-18
KR20150006052A (ko) 2015-01-15
CN104540850B (zh) 2018-05-18
MX2014013319A (es) 2015-07-06
US10253080B2 (en) 2019-04-09
EA028929B1 (ru) 2018-01-31
AU2013255752B2 (en) 2017-11-09
JP6298044B2 (ja) 2018-03-20
JP2015517299A (ja) 2015-06-22
WO2013164484A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
IN2014DN09782A (es)
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
PH12014501702A1 (en) Imidazopyrrolidinone compounds
PH12015500115A1 (en) Glucagon analogues
PH12014502452A1 (en) Gip-glp-1 dual agonist compounds and methods
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
MX2011007930A (es) Conjugados de insulina cristalina.
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
MX2013015176A (es) Co-agonistas del receptor de glucagon/glp-1.
MY170713A (en) Treatment protocol of diabetes type 2
MX2014015423A (es) Analogos de peptido de exedina-4.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2020010693A (es) Uso de peptidos glp-1 de accion prolongada.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2019003619A (es) Formulaciones de bromocriptina.
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MX2014006574A (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
GB201114389D0 (en) Novel compounds
AU2013298343A8 (en) Targeted oesophageal administration of Zn-alpha2-glycoproteins (ZAG), methods and formulations thereof
MX2019008148A (es) Uso de peptidos glp-1 de accion prolongada.
UA106224C2 (en) Crystalline insulin-conjugates
UA92646C2 (ru) применение производных 2-оксоиндолин-3-глиоксиловой кислоты в качестве средств с актопротекторным действием
TN2010000463A1 (en) Compositions and methods for preparing and using same

Legal Events

Date Code Title Description
FG Grant or registration